news
Novel chemotherapeutic pro-drug approved for FIH trial in the UK
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
List view / Grid view
Breast cancer
news
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.
news
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
news
Intraoperative radiotherapy as effective as external beam radiotherapy, finds study
Researchers reveal that for early breast cancer a single dose of targeted intraoperative radiotherapy (TARGIT-IORT) is as effective at preventing breast cancer recurrence as the standard of care.
article
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
news
FDA approves new administration route for Phesgo to treat breast cancer
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
news
EMA recommends updating safety information for HRT and leuprorelin
The EMA has suggested that the safety information be updated for HRT, to reflect a higher risk of breast cancer and recommends new measures for the handling of leuprorelin depot medicines.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
news
Nanoparticle drug delivery could be the future of targeted cancer therapies
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
article
Summarising 2019: a year of firsts for the EMA
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
news
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
news
WHO announces first biosimilar medicine pre-qualification
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
news
More effective, safe drugs drive biobetter market growth
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
news
Proposed biosimilar accepted for review by EMA
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
news
‘Smart drug’ shows promise for metastatic triple-negative breast cancer
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
